HER-2/neu is a tumor antigen in patients with breast and ovarian cancer. Multiple varieties of vaccine strategies are being developed to immunize patients against HER-2/neu. Studies in animal models have demonstrated both T cell and antibody immunity are needed to mediate an antitumor response. Thirty-five patients, immunized with HER-2/neu peptide based vaccines, were evaluated for the generation of HER-2/neu-specific antibody immunity. Sixty percent of patients developed HER-2/neu IgG specific antibody responses to at least one peptide included in their vaccine. Twenty-nine percent of patients developed IgG immunity to the native HER-2/neu protein after peptide immunization. Humoral intramolecular epitope-spreading within the HER-2/neu protein occurred in 49% of immunized patients. Intermolecular epitope-spreading to p53 was evident in 20% of vaccinated patients. Of those patients who developed new immunity to p53, 71% had demonstrated antibody epitope-spreading within HER-2/neu.
INTRODUCTION
The HER-2/neu oncogenic protein is a well-defined tumor antigen in patients with breast and ovarian cancer. Patients with HER-2/neu overexpressing cancers have been shown to have a preexistent antibody immune response to HER-2/neu (1, 2), however, the antibody immunity is of low magnitude. Active immunization is a modality by which low level immunity can be boosted to potentially therapeutic or protective levels. Passive immunization with a HER-2/neu monoclonal antibody, trastuzumab, has been shown to mediate an antitumor response (3) . Inducing antibody immunity by vaccination may result in the generation of durable levels of endogenous HER-2/neu-specific antibody in patients with HER-2/neu overexpressing cancers. We immunized patients with HER-2/neu overexpressing cancers with peptides derived from the HER-2/neu protein (4) . The peptides chosen for immunization were T helper epitopes (4) . Vaccinating patients to augment a CD4 + T cell response, however, may stimulate a concomitant B cell response to neu as has been shown in animal models (5) . We questioned whether patients, immunized to generate a T helper immune response specific for HER-2/neu, would develop new antibody immunity or augment preexistent HER-2/neu-specific antibody immunity.
A neu-specific cellular response has been shown to mediate an antitumor effect after active immunization in neutransgenic mice and there is some evidence that B cells may not be the most important immune effectors in the therapeutic response (6) . However, other evidence demonstrates that both antibody and T cell immunity are required to elicit an antitumor effect in neu-transgenic mice (7, 8) . Therefore, vaccines capable of stimulating both HER-2/neu-specific antibodies and T cells may required to elicit a therapeutic effect.
Data presented here demonstrates that immunized patients can develop both HER-2/neu peptide and proteinspecific antibody responses. Furthermore, a broadening of the humoral immune response, i.e. epitope-spreading, within the HER-2/neu protein and within the tumor itself is evident. These results have implications both for the laboratory evaluation of clinical trials of cancer vaccines as well as the identification of potential tumor rejection antigens unmasked by epitope-spreading.
MATERIALS AND METHODS

Patient Population and Clinical Trial
The University of Washington Human Subjects Division and the United States Food and Drug Administration approved a Phase I trial of HER-2/neu peptide vaccines. Thirty-eight patients with Stage III (n = 13) or IV (n = 18) breast, ovarian (n = 5), or nonsmall cell lung cancer (n = 2) gave informed consent, were enrolled on study, and completed the regimen of six vaccines. The median age of the population was 50 years (range 25-85) and the median time from the patients' last chemotherapy was 6 months (range 1-75). Three vaccine formulations were evaluated, each containing three different peptides (9) . One vaccine consisted of peptides derived from the ECD of HER-2/neu; p42-56 (p42), p98-114 (p98), and p328-345 (p328). An intracellular domain (ICD) vaccine included peptides p776-790 (p776), p927-941 (p927), and p1166-1180 (p1166). The final vaccine formulation consisted of peptides from both domains, p369-386 (p369), p688-703 (p688), and p971-984 (p971).
Subjects received i.d. vaccination monthly for 6 months to the same draining lymph node site. GM-CSF, 100 µg/injection, was used as the vaccine adjuvant. Patients were assessed at baseline and monthly during active immunization for both HER-2/neu T cell and antibody responses. The generation of HER-2/neu-specific T cell immunity and adverse events associated with the study have been previously reported (9) . Thirty-five of the 38 subjects enrolled were evaluable for antibody responses and are reported here. Two of the patients were not evaluable because a serum sample taken before the first vaccine was administered was not available, thus a pretreatment antibody assessment could not be done. One patient had been previously treated with a murine monoclonal antibody specific for HER-2/neu and human anti-mouse antibodies prevented the assessment of HER-2/neu protein specific antibodies utilizing the assays described here. For all analysis, control sera was derived from volunteer donors (n = 200) contributing blood products at the Puget Sound Blood Bank, Seattle, WA. Age range of the control group was 25-65 years.
Determination of Antibody Immunity to HER-2/neu Peptides
Ninty-six-well microtiter plates (Dynex Technologies, Chantilly, VA), were coated with one of 9 peptides, p42, p98, p328, p369, p688, p776, p927, p776 or p1166, at a concentration of 20 µg/mL, diluted with carbonate buffer and added at 50 µL per well alternating with wells coated with 50 µL/well of carbonate buffer alone. One row consisted of purified IgG (Sigma, St. Louis, MO) to generate a standard curve. After overnight incubation, all wells were blocked with 1% casein/PBS, 100 µL/well and incubated at room temperature for 1-2 h. Plates were then washed with a 0.15% casein/1% PBS/0.05% Tween-20 wash buffer four times before the experimental serum diluted in 10% FCS/PBS/1% BSA/25 µg/mL mouse IgG was added at 1:100, 1:200, 1:400, and 1:800 dilutions. Plates were incubated for 2 h at room temperature and then washed four times with casein-based wash and incubated for 45 min at room temperature after addition of 50 µL/well IgG-HRP conjugate (Zymed Laboratories, San Francisco, CA) diluted in 1:10,000 in PBS/BSA buffer. After a final four washes with a casein-based wash buffer, TMB reagent (Kirkegaard and Perry Laboratories, Gaithersburg, MD) was added, 75 µL/well, and the color reaction was read at 640 nm until the well containing the 0.16 µg/mL standard reached an OD of 0.3. Reactions were stopped with 75 µL/well 1 N HCL and read at 450 nm. The OD of each serum dilution was calculated as the OD of the peptide-coated wells minus the OD of the buffer-coated wells. Values for µg/mL were calculated from the log-log equation of the line for the standard curve on each plate. A positive sample was defined as an antibody concentration greater than the mean of a volunteer blood donor population and 3 standard deviations, 0.85 µg/mL (0.07 ± 0.26) (n = 108). We choose this positive cutoff by assuming a normal distribution of values for the control population and selecting a value that would allow a 99% confidence interval. The probability that any value obtained from a control sample would be above the cutoff value, i.e. a "positive," is less than 0.3%. Thus, samples that are positive would most likely be due to active immunization since the preimmunization samples, for the most part, are of the same magnitude as controls. Some patients did have preexistent detectable antibody immunity to an immunizing peptide and were only considered to have responses if they boosted the antibody level to twice their baseline value. The assay was linear over the range of antibody concentrations tested and had a correlation coefficient of 0.97. Based on repeated measures of 20 volunteer and 20 experimental sera over a 6-month period the intra-and interassay coefficient of variations were 12 and 18%, respectively.
Determination of Antibody Immunity to HER-2/neu and Control Proteins
Analyses were performed as previously described (10) . Serum from a patient with a documented HER-2/neuspecific antibody response was used as a positive control.
A positive sample was again defined as an antibody concentration greater than the mean of a volunteer blood donor population and 3 standard deviations, 1.10 µg/mL (0.20 ± 0.4) (n = 200). Positive results were confirmed by Western blot analysis. Some patients did have preexistent detectable antibody immunity to the HER-2/neu protein and were only considered to have responses if they boosted the antibody level to twice their baseline value. The specificity of the assay was 78% and sensitivity 90%. The assay was linear over the range of antibody concentrations tested and had a correlation coefficient of 0.99. Based on repeated measures of 20 volunteer and 20 experimental sera over a 6-month period the intra-and interassay coefficient of variations were 15 and 9%, respectively. ELISA for tetanus toxoid and Candida were performed using a similar method to that described above with the following modifications. Purified tetanus toxoid (Lederle Laboratories, Pearl River, NY) was used to coat experimental wells diluted to 0.01Lf/mL and Candida antigen (Allermed Laboratories, San Diego, CA) was used to coat experimental wells diluted 1:20,000 (w/v). The standard curve in these assays was based on values ranging from 0.62-0.005 µg/mL IgG. Color reactions were stopped when 0.16 µg/mL value reached 0.3 OD at 640 nm.
Determination of Antibody Immunity to p53
ELISA was used to determine p53 antibodies as described with HER-2/neu with minor modifications and adapted from previously published methods (11) . Plates were coated with a murine monoclonal antibody specific for p53 (ATCC TIB-116, Manassas, VA) diluted to a concentration of 20 µg/mL with carbonate buffer. BT-20 cell line, a breast cancer cell line that has abundant wild type as well as mutated p53, was used as a source of p53 protein (ATCC HTB-19). Serum from a lung cancer patient with high levels of p53-specific antibodies was used as a positive control. A positive sample was again defined as an antibody concentration greater than the mean of a volunteer blood donor population and 3 standard deviations, 0.91 µg/mL (0.16 ± 0.25) (n = 175). Positive results were confirmed by Western blot analysis (11) . Some patients did have preexistent detectable antibody immunity to the p53 protein and were only considered to have responses if they boosted the antibody level to twice their baseline value. The specificity of the assay was 86% and sensitivity 100%. The assay was linear over the range of antibody concentrations tested and had a correlation coefficient of 0.95. Based on repeated measures of 20 volunteer and 20 experimental sera over a 6-month period the intraand interassay coefficient of variations were 15 and 12%, respectively. To assess the overall immunogenicity of a particular peptide we evaluated the mean responses of all patients immunized with an individual peptide. Differences in antibody immunity between pre-and postimmunization samples were significant for p42 ( p = .028), p776 ( p = .028), p369 ( p = .002), and p688 ( p = .018). The mean pre-and postimmunization responses were not statistically different for peptides p98 ( p = .068), p927 ( p = .483), p1166 ( p = .180), p971 ( p = .161), and p328 ( p = .173). Figure 2 demonstrates the magnitude of the antibody response generated to the HER-2/neu protein after peptide immunization. One patient had a preexistent antibody response to HER-2/neu protein prior to the start of the vaccination series. That patient did not boost immunity after active immunization. Ten of the 35 patients (29%) developed HER-2/neu protein specific antibody immunity after peptide immunization (range of all responses; 0-9.3 µg). The development of antibody immunity to a specific HER-2/neu peptide or immunization with a particular peptide vaccine did not correlate with the development of a HER-2/neu protein specific antibody response.
RESULTS
Patients Immunized with HER-2/neu Peptide Based Vaccines Can Develop HER-2/neu Peptide Specific
Antibody Immunity Figure 1 shows the preimmunization and maximal peptide-specific antibody responses for all patients. Panel A depicts results from the 12 patients who received the ECD vaccine. Two of 12 (17%) patients developed antibodies to p42 (range of all responses; 0-6.5 µg), 1 patient had a preexistent response and boosted that response with immunization, from 3.5 to 6.5 µg. Two (17%) of the patients developed antibodies to p98 (range of all responses; 0-1.1 µg), and 2 (17%) developed an immune response to p328 (range of all responses; 0-5.7 µg). The two patients with a preexistent response to p328 did not boost immunity.
Patients Immunized with HER-2/neu Peptide Based Vaccines Can Develop HER-2/neu Protein Specific Antibody Immunity
We questioned whether the antibody immunity elicited was specific for HER-2/neu vaccination as GM-CSF could potentially act as a generalized immunostimulatory agent. For this reason we assessed antibody immunity to two common antigens, tetanus toxoid and Candida, in each patient during the time of active immunization. The mean tetanus antibody response in this population prior to initiating the HER-2/neu peptide vaccine regimen was 40.1 µg/mL and postimmunization was 40 µg/mL ( p = 0.949). Similarly, the mean Candida antibody response prior to initiating the HER-2/neu peptide vaccine regimen was 7.6 µg/mL and postimmunization was 6.2 µg/mL ( p = 0.331). Thus, there did not appear to be a generalized nonspecific augmentation in antibody immunity during the course of active immunization using GM-CSF as an adjuvant.
Humoral Intramolecular Epitope-Spreading Can Develop After HER-2/neu Peptide Immunization
Some patients developed antibody immunity to at least one peptide that was not in their immunizing mix, i.e. epitope spreading. Seventeen of the 35 patients (49%) had evidence of intramolecular humoral epitope-spreading within the HER-2/neu protein. Example patients are shown in Fig. 3 . Immunization with a particular peptide vaccine did not correlate with the development epitopespreading. Of note, 7 of the 10 patients (70%) who developed HER-2/neu protein specific antibody immunity after peptide immunization also demonstrated intramolecular epitope-spreading.
Humoral Intermolecular Epitope-Spreading Can Develop After HER-2/neu Peptide Immunization
We questioned whether the broadening of the humoral immune response extended beyond the HER-2/neu protein by evaluating immunity to p53. p53 is immunogenic in patients with breast cancer (12) and should be mutated and present as an abundant form of protein in tumor cells in over half of all breast cancers. Seven of 35 patients (20%) developed new antibody immunity to p53 during the 7-month vaccine course, examples are shown in Fig. 4 . The range of positive p53 IgG antibody responses was 1.4-9.6 µg/mL at a titer of 1:25. Five of the 7 (71%) were patients who demonstrated intramolecular epitope-spreading within HER-2/neu. The other two patients who developed p53 antibody immunity did not display evidence of intramolecular epitope-spreading, but were patients who developed HER-2/neu protein antibody immunity after peptide vaccination.
DISCUSSION
The ability to vaccinate with peptides and generate protein-specific antibodies in humans would be important in contemplating the design of peptide based vaccines targeting putative ligand-binding regions of the HER-2/neu protein thereby generating autologous antibodies that may mimic the effects of trastuzumab. Data presented here demonstrates the majority of patients who completed the course of six immunizations developed HER-2/neu peptide specific IgG antibody immunity, however, only a minority developed antibodies that responded to the intact HER-2/neu protein after peptide vaccination. Furthermore, humoral intramolecular epitope-spreading occurred within the HER-2/neu protein epitope-spreading extended to at least one other immunogenic breast cancer related protein, p53.
The majority of patients could be successfully immunized to develop HER-2/neu peptide specific antibody immunity. Although the peptides used in these vaccines were not specifically chosen to elicit antibody immunity to functional epitopes present in the extracellular domain of HER-2/neu, more directed approaches of determining functional HER-2/neu-specific B cell peptide epitopes have been developed. Using phage display techniques investigators have identified the peptide epitopes recognized by three well-characterized HER-2/neu-specific monoclonal antibodies (13) . One of the monoclonal antibodies directly inhibited the proliferation of HER-2/neu overexpressing tumor cells in vitro. Mice immunized with the peptide region recognized by that monoclonal antibody were able to inhibit the growth of neu overexpressing tumor in vivo (13) . Similarly, B cell epitopes can be predicted by computer modeling (14) . Identification of putative HER-2/neu B cell epitopes derived from the HER-2/neu extracellular domain and subsequent immunization of animals with these peptides resulted in high titer HER-2/neu peptide specific antibodies that were cross reactive with the native HER-2/neu receptor and inhibited the development of spontaneous tumors in neu transgenic mice (14) . In some of the patients described in this study, the level of IgG antibody achieved was well above the recommended trough levels for trastuzumab therapy, i.e. 10 µg/mL (15) . The feasibility of immunizing patients with HER-2/neu peptides to generate a peptide specific antibody response is demonstrated in this study.
If they are to be therapeutic or protective, peptidespecific antibodies must be capable of binding native protein to be functional in vivo. Only a minority of patients immunized developed antibody immunity to the native HER-2/neu protein as assessed by ELISA and immunoblot. These are several reasons why this method of immunization was inefficient in generating HER-2/neu protein specific antibody immunity in the majority of patients. One potential explanation is that the epitopes chosen were less appropriate for the generation of native HER-2/neu-specific antibodies than those that would have been predicted by other methods. An alternative explanation is that the vaccine adjuvant was not optimal. The adjuvant used can greatly influence the character of the immune response generated after vaccination. The vaccine described here utilized GM-CSF as an adjuvant to mobilize skin dendritic cells, Langerhans' cells, in vivo (16) . Injection of GM-CSF as a vaccine adjuvant was shown to be associated with the generation of a Th1 immune response stimulating interferon gamma secretion and the development of a predominant cellular rather than humoral immune response (17) . The use of GM-CSF as a vaccine adjuvant has been studied recently in multiple vaccine models due to the low incidence of side effects related to the adjuvant in human clinical trials. Similar to the data reported in this study, GM-CSF was not found to appreciably enhance antibody responses to a Hepatitis B vaccine (18) . Therefore, future peptide-based vaccine studies must optimize immunization strategies to augment HER-2/neu protein antibody responses after peptide immunization. Despite the fact that HER-2/neu IgG antibody responses were not optimal in terms of the magnitude of response generated, the vaccine strategy used here was successful in initiating humoral epitope-spreading. Epitope-spreading has been associated with immunizations generating a Th1 microenvironment and it is presumed the resultant inflammatory response enhances the evolution of immunity (19) .
Both intramolecular and intermolecular humoral epitope-spreading occurred after vaccination. Analysis of the T cell responses induced on this trial demonstrated that intramolecular epitope-spreading also occurred at the level of the CD4 + T cell (9) . However, data presented here demonstrates that immunity also spread to at least one additional breast cancer antigen besides HER-2/neu. Epitope-spreading is a phenomenon that was first reported in autoimmune disease and represents a broadening of the immune response from a single epitope to additional epitopes within a protein or even to additional immunogenic proteins within a lesion (20) . In autoimmune disease the presence of epitope-spreading has been associated with tissue damage (19) . Epitope-spreading has also been described in cancer, occurring after certain immunotherapies such as vaccines. Although the endpoint of many clinical trials of cancer vaccines is the evolution of measurable immunity, recent evidence suggests that epitope-spreading may be a more significant predictor of effective immunity (9) or even of clinical response (21) . The identification of both intra-and intermolecular humoral epitope-spreading epitope has not previously been reported following immunization with a cancer vaccine. Not only may the development of epitope-spreading predict clinical response in future studies, the ability to use immune sera derived from these patients may allow the identification of tumor rejection antigens. As epitope-spreading is associated with tissue destruction in autoimmune disease, epitopespreading in cancer could be used to identify the antigens to which an immune response is potentially linked with tissue destruction.
